Covid-19: German BioNTech to seek approval of vaccine for children ages 5 to 11

The study data on younger children from six months of age is also expected by the end of the year.

RIO DE JANEIRO, BRAZIL - BioNTech is expected to apply for approval to use its Covid-19 vaccine in children as young as 5 years old across the globe in the coming weeks, and preparations for a launch are underway. The biotech company's two top executives spoke to German newsmagazine 'Der Spiegel'.

"Already in the course of the next few weeks, we will present the results of our test in 5- to 11-year-olds to regulatory agencies around the world and apply for approval of the vaccine in this age group, including here in Europe," their chief medical officer . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?